New components for whole-cell culture

LAP892AUndetermined Publication Date: 2026-04-03TS BIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP892
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-09-23
Filing Date
2021-09-17
Publication Date
2026-04-03

AI Technical Summary

Technical Problem

Current culture media for adipose-derived mesenchymal stem cells are not optimized for proliferation and resistance to oxidative stress, particularly for human adipose-derived stem cells, and existing media suitable for embryonic stem cell-derived mesenchymal stem cells are not effective for human adipose-derived stem cells.

Method used

A novel medium composition containing ascorbic-acid-2-phosphate, vitamin E, tomato extract, Ailanthus altissima leaf extract, baicalein, luteolin, quercetin, ascorbyl-2,6-dipalmitate, vitamin D3, gamma-glutamyl cysteine, and putrescine is developed to enhance proliferation and oxidative stress resistance in adipose-derived mesenchymal stem cells.

Benefits of technology

The novel composition significantly improves the resistance to oxidative stress and proliferation of adipose-derived mesenchymal stem cells, optimizing their culture conditions and enhancing their therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

What is prepared is a novel medium for culturing human-derived stem cells (hAD-MScs) with increased resistance to oxidative stress and proper stem cell proliferation.
Need to check novelty before this filing date? Find Prior Art

Description

A NOVEL COMPOSITION FOR STEM CELL CULTURE

[0001] This application claims priority to Korean Patent Application No. 10-2020-0122849 filed on September 23, 2020, and all the contents of which are incorporated by reference in their entirety.

[0002] The present invention relates to a novel composition for culturing stem cells, and more particularly, to a novel composition for culturing adipose-derived mesenchymal stem cells for culturing stem cells.

[0003] The present disclosure relates to a novel composition for culturing stem cells, and more particularly, to a novel composition for culturing stem cells for culturing adipose-derived mesenchymal stem cells.

[0004] Stem cells are progenitor cells with the ability to self-replicate and differentiate into various tissues by appropriate signals, which form the organs of the human body from the stages of development and play an important role in restoring the functions of organs and tissues after growth. Stem cells include embryonic stem cells obtained from blastocysts in the early stages of development, and adult stem cells obtained from adults or placenta in which the development process is completed. The use of embryonic stem cells faces many ethical problems with regard to the use of living organisms, and therefore, their practical use is limited. In contrast, adult stem cells have the specificity to differentiate according to the characteristics of the organs after transplantation in vivo and the flexibility to cross-differentiate into different types of cells from the characteristics of original cells, and as it has been identified that adult stem cells have the potential to be differentiated into various cells, the cell therapy potential via adult stem cells has been increasing. Among the methods for obtaining adult stem cells, the method which is easiest and is able to obtain the most abundant amount is to isolate adipose stem cells derived from adipose tissue, and these stem cells are called adipose-derived stem cells (ASCs). Since it is easy to collect a large amount of tissue from adipose tissue, adipose tissue provides good conditions for obtaining stem cells. ASCs show stable growth and proliferation during culture, and they can be differentiated into various cells when their differentiation is induced. Therefore, there is a need for the development of a culture composition capable of obtaining adipose-derived mesenchymal stem cells in large quantities. In this regard, Korean Patent Application Publication No. 2020-0028865 disclose a medium for direct differentiation of mesenchymal stem cells derived from pluripotent stem cells; a method for preparing mesenchymal stem cells using the same, and the mesenchymal stem cells prepared thereby.

[0005] However, in the case of the related art above, it relates to a medium for direct differentiation of embryonic stem cell-derived mesenchymal stem cells, which is not suitable for proliferation of human adipose-derived stem cells.

[0006] The present disclosure is designed to solve several disadvantages including those described above, and in accordance with an exemplary embodiment, the present invention disclosure provides a novel medium composition for culturing stem cells, in which inhibitory activity against oxidative stress is increased and stem cell proliferation ability is optimized. However, these are exemplary purposes, and the scope of the present disclosure is not limited by the same.

[0007] According to an aspect of the present disclosure, there is provided a medium composition for culturing adipose-derived mesenchymal stem cells, which contains: basal medium; 100-150 μg / mL of ascorbic-acid-2-phosphate (AA2P) and 0.5-2 μM vitamin E; 5-15 μg / mL of a tomato extract; 50-200 μg / mL of an extract ofAilanthus altissimaleaves; 200-400 nM baicalein; 500-700 nM luteolin; 4-6 μM quercetin; 10-30 μM ascorbyl-2,6-dipalmitate; 5-15 μM vitamin D3; 1.5-3.5 μM gamma-glutamyl cystein ester; and 5-20 μM / mL of putrescine.

[0008] According to another aspect of the present disclosure, there is provided a method forex vivoculture of adipose-derived stem cells, which includes a step of culturing adipose-derived stem cells isolated outside the body of a subject in the medium for culturing adipose-derived stem cells.

[0009] A novel composition for culturing stem cells of the present disclosure prepared as described above has improved resistance to cell proliferation and oxidative stress of stem cells, and thus, the composition can be used as a culture composition for optimizing stem cell ability of human adipose-derived stem cells (hAD-MSCs). Certainly, the scope of the present disclosure is not limited by these effects.

[0010] Although the novel composition for stem cell culture has been described with reference to the specific embodiments, it is not limited thereto. Therefore, it will be readily understood by those skilled in the art that various modifications and changes can be made thereto without departing from the spirit and scope of the present invention defined by the appended claims.

[0011] Exemplary embodiments can be understood in more detail from the following description taken in conjunction with the accompanying drawings, in which:

[0012] FIG. 1A to 1E shows the result of the addition of Vitamin E in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 1A is a schematic diagram showing an experimental process in the method. FIG. 1B is a series of fluorescence microscope images showing the result of the experiment. FIG. 1C is a series of graphs showing the result of GSH analysis. FIG. 1D is a histogram showing the result of the experiment. FIG. 1E is a graph showing oxidative stress resistant capacity according to the concentration of treated Vitamin E.

[0013] FIGs. 2A to 2E shows the result of the addition of AA2P in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 2A is a schematic diagram showing an experimental process in the method. FIG. 2B is a series of fluorescence microscope images showing the result of the experiment. FIG. 2C is a series of graphs showing the result of GSH analysis. FIG. 2D is a histogram showing the result of the experiment. FIG. 2E is a graph showing oxidative stress resistant capacity according to the concentration of treated AA2P.

[0014] FIGs. 3A to 3E shows the result of the addition of tomato extract in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 3A is a schematic diagram showing an experimental process in the method. FIG. 3B is a series of fluorescence microscope images showing the result of the experiment. FIG. 3C is a series of graphs showing the result of GSH analysis. FIG. 3D is a histogram showing the result of the experiment. FIG. 3E is a graph showing oxidative stress resistant capacity according to the concentration of treated tomato extract.

[0015] FIGs. 4A to 4E shows the result of the addition of extract ofAilanthus altissimaleaves in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 4A is a schematic diagram showing an experimental process in the method. FIG. 4B is a series of fluorescence microscope images showing the result of the experiment. FIG. 4C is a series of graphs showing the result of GSH analysis. FIG. 4D is a histogram showing the result of the experiment. FIG. 4E is a graph showing oxidative stress resistant capacity according to the concentration of treated extract ofAilanthus altissimaleaves.

[0016] FIGs. 5A to 5E shows the result of the addition of baicalein in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 5A is a schematic diagram showing an experimental process in the method. FIG. 5B is a series of fluorescence microscope images showing the result of the experiment. FIG. 5C is a series of graphs showing the result of GSH analysis. FIG. 5D is a histogram showing the result of the experiment. FIG. 5E is a graph showing oxidative stress resistant capacity according to the concentration of treated baicalein.

[0017] FIGs. 6A to 6E shows the result of the addition of quercetin in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 6A is a schematic diagram showing an experimental process in the method. FIG. 6B is a series of fluorescence microscope images showing the result of the experiment. FIG. 6C is a series of graphs showing the result of GSH analysis. FIG. 6D is a histogram showing the result of the experiment. FIG. 6E is a graph showing oxidative stress resistant capacity according to the concentration of treated quercetin.

[0018] FIGs. 7A to 7E shows the result of the addition of quercetin in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 7A is a schematic diagram showing an experimental process in the method. FIG. 7B is a series of fluorescence microscope images showing the result of the experiment. FIG. 7C is a series of graphs showing the result of GSH analysis. FIG. 7D is a histogram showing the result of the experiment. FIG. 7E is a graph showing oxidative stress resistant capacity according to the concentration of treated quercetin.

[0019] FIGs. 8A to 8E shows the result of the addition of ascorbyl palmitate in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 8A is a schematic diagram showing an experimental process in the method. FIG. 8B is a series of fluorescence microscope images showing the result of the experiment. FIG. 8C is a series of graphs showing the result of GSH analysis. FIG. 8D is a histogram showing the result of the experiment. FIG. 8E is a graph showing oxidative stress resistant capacity according to the concentration of treated ascorbyl palmitate.

[0020] FIGs. 9A to 9E shows the result of the addition of vitamin D3 in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells. FIG. 9A is a schematic diagram showing an experimental process in the method. FIG. 9B is a series of fluorescence microscope images showing the result of the experiment. FIG. 9C is a series of graphs showing the result of GSH analysis. FIG. 9D is a histogram showing the result of the experiment. FIG. 9E is a graph showing oxidative stress resistant capacity according to the concentration of treated vitamin D3.

[0021] FIGs. 10A to 10C shows the result of the addition of antioxidants in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells(in which baicalein, quercetin, luteolin were used). FIG. 10A is a schematic diagram showing an experimental process in the method. FIG. 10B is a series of fluorescence microscope images showing the result of the experiment. 10C is a graph showing oxidative stress resistant capacity according to the concentration of treated antioxidants.

[0022] FIGs. 11A to 11C shows the result of the addition of various components in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells(in which a tomato extract, an extract ofAilanthus altissimaleaves, AA2P, ascorbyl palmitate, vitamin E and vitamin D3 were used). FIG. 11A is a schematic diagram showing an experimental process in the method. FIG. 11B is a series of fluorescence microscope images showing the result of the experiment. 11C is a graph showing oxidative stress resistant capacity according to the concentration of treated various components.

[0023] FIGs. 12A to 12C shows the result of the addition of various components in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells(in which a tomato extract, an extract ofAilanthus altissimaleaves, ascorbyl palmitate and vitamin D3 were used). FIG. 12A is a schematic diagram showing an experimental process in the method. FIG. 12B is a series of fluorescence microscope images showing the result of the experiment. 12C is a graph showing oxidative stress resistant capacity according to the concentration of treated various components.

[0024] FIGs. 12D to 12F shows the result of the addition of various components in the method of screening a composition for culturing adipocyte-derived mesenchymal stem cells(in which baicalein, quercetin, luteolin, AA2P and vitamin E were used). FIG. 12D is a schematic diagram showing an experimental process in the method. FIG. 12E is a series of fluorescence microscope images showing the result of the experiment. 12F is a graph showing oxidative stress resistant capacity according to the concentration of treated various components.

[0025] FIG. 13 is a graph analyzing the doubling time of human adipose-derived stem cells, in which the effect of improving antioxidant activity specific to human adipose-derived stem cells was confirmed through comparison with human umbilical cord blood-derived stem cells.

[0026] FIG. 14 is a graph analyzing the results of doubling time of human adipose-derived stem cells after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0027] FIG. 15 is a graph analyzing the results of the cumulative population doubling level of human adipose-derived stem cells after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0028] FIG. 16 is images observed under a microscope after culturing human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0029] FIG. 17 is a graph analyzing the number of colonies after culturing human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0030] FIG. 18 is a series of images in which colonies were observed after culturing human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0031] FIG. 19 is graphs analyzing the GSH level of human adipose-derived stem cells after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0032] FIG. 20 is graphs analyzing the GSH heterogeneity of human adipose-derived stem cells after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0033] FIG. 21 is graphs analyzing the resistance of human adipose-derived stem cells to oxidative stress after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0034] FIG. 22 is a graph analyzing the ability of human adipose-derived stem cells to inhibit T-cell proliferation after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0035] FIG. 23 is a graph analyzing the ability of human adipose-derived stem cells to differentiate into regulatory T-cells after culturing the human adipose-derived stem cells using three types of basal media (C1, C2, C3) of the present disclosure.

[0036] Hereinafter, specific embodiments will be described in detail with reference to the accompanying drawings.

[0037] Definition of Terms:

[0038] As used herein, the term “stem cell” refers to an undifferentiated biological cell capable of differentiating into a specific cell, and a cell capable of proliferating in an undifferentiated state. These stem cells are characterized by having pluripotency to differentiate into various cells, and they can be classified into “embryonic stem cells (ESCs)”, which are derived from embryos and have pluripotency capable of differentiating into various cells, and “adult stem cells (ASC)”, which are derived from adults and have totipotency capable of forming individuals. In the “embryonic stem cell”, an egg and a sperm combine to become a fertilized egg, and the fertilized egg, which starts as a single cell, becomes a blastocyst consisting of several cells through cell division, and the cells inside the blastocyst are cells derived from the inner cell mass formed and these cells have the ability to differentiate into cells of all tissues in one individual, such as blood, bone, skin, and liver. In addition, the “adult stem cells” refer to undifferentiated cells that can be amplified by somatic cell division to replace dead cells after development and regenerate damaged tissues, and these cells include neural stem cells, hematopoietic stem cells, mesenchymal stem cells, endothelial stem cells, etc. Although these adult stem cells have a limited differentiation capability than the embryonic stem cells, they can also be differentiated into cells of a lineage different from that of the origin, which is called trasndifferentiation or plasticity. Since adult stem cells are stable in differentiation and there is no possibility of cancer cells, they have already reached a stage where they can be applied clinically. Additionally, unlike embryonic stem cells, adult stem cells have no destruction of the fertilized egg, thus not raising an ethical issue, and the number of stem cells that can be obtained is small, and adult stem cells have a disadvantage in that these cells are difficult to culture.

[0039] DETAILED DESCRIPTION OF THE INVENTION

[0040] According to an aspect of the present disclosure, there is provided a medium composition for culturing adipose-derived mesenchymal stem cells, which contains: basal medium; 100-150 μg / mL of ascorbic-acid-2-phosphate (AA2P) and 0.5-2 μM vitamin E; 5-15 μg / mL of a tomato extract; 50-200 μg / mL of an extract ofAilanthus altissimaleaves; 200-400 nM baicalein; 500-700 nM luteolin; 4-6 μM quercetin; 10-30 μM ascorbyl-2,6-dipalmitate; 5-15 μM vitamin D3; 1.5-3.5 μM gamma-glutamyl cystein ester; and 5-20 μM / mL of putrescine.

[0041] In the medium composition above, the medium composition may contain 120-130 μg / mL of AA2P and 0.8-1.5 μM vitamin E; 10-12 μg / mL of a tomato extract; 70-150 μg / mL of an extract ofAilanthus altissimaleaves; 250-350 nM baicalein; 550-650 nM luteolin; 4.5-5.5 μM quercetin; 15-25 μM ascorbyl-2,6-dipalmitate; 7-13 μM vitamin D3; 1.7-3.2 μM gamma-glutamyl cystein ester; and 7-15 μM / mL of putrescine.

[0042] Additionally, the basal medium may be α-MEM and the composition may further contain 5-15% fetal bovine serum (FBS) and 0.5-2% penicillin-streptomycin (PS).

[0043] According to another aspect of the present disclosure, there is provided a method forex vivoculture of adipose-derived stem cells, which includes a step of culturing adipose-derived stem cells isolated outside the body of a subject in the medium for culturing adipose-derived stem cells.

[0044] The culture medium of the present disclosure may further contain mesenchymal stem cell growth factors that affect the growth of mesenchymal stem cells. Growth factors of the mesenchymal stem cells are, for example, insulin, hydrocortisone, epidermal growth factor (EGF), leukemia inhibitory factor (LIF), granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin (EPO), fibroblast growth factor (FGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), stem cell factor (SCF), transforming growth factor (TGF), etc.

[0045] Hereinafter, the present disclosure will be described in more detail through Examples. However, the present disclosure is not limited to these Examples disclosed below, but may be implemented in various different forms, and the following Examples are provided to ensure that the disclosure of the present disclosure is complete, and to fully inform those of ordinary skill in the scope of the disclosure.

[0046] Example 1: Basic screening

[0047] The present inventors performed a screening to discover substances that enhance antioxidant activity in human adipose-derived stem cells (hAD-MSC). Specifically, the cells were seeded with human adipose-derived stem cells in a well plate (4 × 103cells / well) and were cultured for 24 hours after adding 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) to α-MEM, and the medium was replaced with a culture medium in which the materials for treatment were diluted at various concentrations and treated for 24 hours. Then, the cells were treated with an antioxidant and incubated for 2 hours, and subjected to Mito-FT staining and endpoint measurement. As the treatment materials, vitamin E, AA2P, a tomato extract, an extract ofAilanthus altissimaleaves, baicalein, quercetin, luteolin, ascorbyl palmitate, and vitamin D3 were used.

[0048] Example 2: Flow cytometry

[0049] For measurement of GSH distribution in MSCs through flow cytometry, 4, 7, and 15 subcultures of human adipose-derived stem cells (hAD-MSCs) were prepared, and 70,000 cells were added per well of a 6-well cell culture plate, and then incubated at 37℃ for 24 hours. The medium used at this time contained 10% fetal bovine serum and 1X penicillin-streptomycin in α-MEM. After removing the medium, RSL3, which is a glutathione peroxidase 4 (GPX4) inhibitor, was added thereto at a concentration of 0.1 / 0.5 / 1 μM and incubated at 37℃ for 1.5 hours. The medium used at this time contained 10% fetal bovine serum and 1X penicillin-streptomycin in α-MEM. After removing the medium containing RSL3, Mito-FreSHtracer were added thereto and incubated at 37℃ for 1.5 hours. The medium used at this time contained 10% fetal bovine serum and 1X penicillin-streptomycin in α-MEM. After removing the medium containing Mito-FreSHtracer, the cells were washed twice with 2 mL of DPBS. After adding 250 μL of TrypLE Express thereto, the cells were allowed to react at 37℃ for 2 minutes and 30 seconds, an equal amount of DPBS containing 2% FBS was added thereto so as to detach the cells from the plate. The cells detached from the plate were transferred to a FACS tube and stored on ice, and the fluorescence value was measured using a flow cytometry device.

[0050] Example 3: Fluorescence imaging

[0051] For measurement of GSH distribution using fluorescence imaging, 4, 7, and 15 subcultures of human adipose-derived stem cells (hAD-MSCs) were prepared, and 7,000 cells / 100 μL A11 were added per well of a 96-well cell culture plate, and then incubated at 37℃ for 24 hours. The medium used at this time contained 10% fetal bovine serum and 1X penicillin-streptomycin in α-MEM. After removing the medium, 100 μL of RSL3 (i.e., a glutathione peroxidase 4(GPX4) inhibitor) was added thereto at a concentration of 0.1 / 0.5 / 1 μM and incubated at 37℃ for 2 hours. The medium used at this time contained 10% fetal bovine serum and 1X penicillin-streptomycin in α-MEM. After removing the medium containing RSL3, 100 μL each of 15 μM Mito-FreSHtracer was added thereto and incubated at 37℃ for 1 hour. The medium used at this time contained Hanks’balanced salt solution (HBSS) containing 10 mM HEPES. In order to remove Mito-FreSHtracer in the medium before measurement, the medium was replaced with HBSS containing 10 mM HEPES, and then the fluorescence image was measured using Operetta, a confocal imaging device.

[0052] Example 4: Histogram analysis

[0053] After measuring the fluorescence values of F510 (a fluorescence value when Mito-FreSHtracer is bound to an SH group) and F580 (a self-fluorescence value in a state where Mito-FreSHtracer is not bound to an SH group) in each cell, the value obtained by dividing the F510 value by the F580 value was obtained as the F510 / F580 ratio value, which means the average value of intracellular GSH. Using the prism 5 program, the F510 / F580 ratio value of each cell is shown as the X-axis, and the percentage(%) amount of cells corresponding to the F510 / F580 ratio value is shown on the Y-axis as a histogram. Alexa 430 / PE (F510 / F580) parameters were analyzed in all samples using Flowjo software for analyzing flow cytometry, GSH High (right peak) and Low cell (left peak) were divided so as to indicate the percentage of the corresponding cells based on the point where the histogram showing the distribution of F510 / F580 was divided into two peaks.

[0054] As a result, it was found that vitamin E has cytotoxicity from 25 μM, AA2P from 250 μg / mL, the tomato extract from 10 μg / mL, the extract ofAilanthus altissimaleaves from 200 μg / mL, baicalein from 0.625 μM, quercetin from 10 μM, luteolin from 1.25 μM, ascorbyl palmitate from 50 μM, and vitamin D3 from 25 μM (FIGs. 1A to 9E).

[0055] Example 5: Comparison with other stem cells

[0056] The present inventors have confirmed the effect of enhancing antioxidant activity specific to human adipose-derived stem cells through comparison with human umbilical cord-derived stem cells (hUC-MSCs) and human cord blood-derived stem cells (hUCB-MSCs). The experimental method was performed under the same conditions as in Example 1 above.

[0057] As a result, it was confirmed that the antioxidant activity-enhancing substances discovered according to an embodiment of the present disclosure were specific to human adipose-derived stem cells(FIGs. 10A to 13).

[0058] Example 6: Preparation of medium

[0059] The present inventors have prepared a medium using the antioxidant activity-enhancing substances selected according to the screening method performed above. First, a basal medium C1 was prepared by adding 120 ㎍ / mL of ascorbic-acid-2-phosphate (AA2P) and 1 μM vitamin E to a medium, which contained 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) in α-MEM. Additionally, a basal medium C2 was prepared by adding 10 μg / mL of a tomato extract, 100 μg / mL of an extract ofAilanthus altissimaleaves, 300 nM baicalein, 600 nM luteolin, and 5 μM quercetin to the above medium. Furthermore, a medium C3 was prepared by adding all of the materials contained in C1 and C2 to the above medium, and further adding 20 μM ascorbyl 2,6-dipalmitate, 10 μM vitamin D3, 2.5 μM γ-glutamyl cystein ester, and 10 μM / mL of putrescine to the above medium.

[0060] Example 7: Thawing and culturing of cells

[0061] A frozen vial stored under refrigeration was placed in a water bath for 1 minute and then the thawed solution in the vial was mixed with 4 mL of a culture medium in a 50 mL conical tube. Thereafter, the mixture was centrifuged at 4℃ and at 1,700 rpm for 5 minutes, and the supernatant was removed after confirming the presence of a pellet by the naked eye. After suspending the cells by adding 5 mL of a culture medium to the pellet, a sample for measuring the number of cells was collected, and the culture medium and cells were mixed and placed into a culture vessel so as to measure the number of cells (based on one T-75 flask, 5.0×106cells / 12 mL). The culture vessel was placed in a 5% CO2incubator at 37℃, and the culture medium was replaced on Day 2 from the day of culture initiation, and cultured to a confluency of 80% or more of the culture vessel area (Day 3 from the day of culture initiation).

[0062] Example 8: Collection of cells and subculture

[0063] The culture medium in the culture vessel was removed, and 5 mL of DPBS was added to wash the bottom of the culture vessel and then removed. Then, 1.5 to 2 mL of the cell treatment solution was added thereto, and the cells were placed in a 5% CO2incubator at 37℃ for 3 minutes, and whether the cells became single cells was checked under a microscope. Thereafter, 5 mL of the culture medium was added, and the cells were harvested and transferred to a 50 mL conical tube. Then, the culture medium was added into the culture vessel to a total volume of 10 mL and the cells were collected once again. The resultant was centrifuged at 4℃ at 1,700 rpm conditions for 5 minutes, and the supernatant was removed after confirming the presence of a pellet by the naked eye. After suspending the cells by adding 10 mL of DPBS or a culture medium to the pellet, a sample for measuring the number of cells was collected and the number of cells was counted, and the culture medium and cells were mixed and placed into a culture vessel (based on one T-75 flask, 5.0×106cells / 12 mL). The culture vessel was placed in a 5% CO2incubator at 37℃, and the culture medium was replaced on Day 2 from the day of culture initiation, and cultured to a confluency of 80% or more of the culture vessel area (Day 3 from the day of culture initiation).

[0064] Example 9: Measurement of number and viability Cells

[0065] The sample for measurement of cell number was collected using a 20 μL pipette and diluted in 20 μL of Trypan blue in a 1:1 ratio. The resultant was placed into a hemocytometer, and the number of cells was measured by checking under a microscope. The number of cells was calculated by Equation 1 below, and the viability was calculated by Equation 2 below.

[0066] (Equation 1)

[0067] Number of cells × dilution × 1 / 4 × total volume(capacity).

[0068] (Equation 2)

[0069] Number of living cells / (number of living cells + number of dead cells) × 100.

[0070] Example 10: Antioxidation test

[0071] 10-1: CPDL(Cell Population Doubling Time)

[0072] The present inventors analyzed the CPDL of human adipose-derived stem cells(BA200220-1, BA200220-2, and BA200220-3) using three types of antioxidant-added basal media(C1, C2, and C3), a basal medium, and a commercialized medium for comparison of the present disclosure. Specifically, after thawing the three types of p1 cell stock, each of the 4 passage subcultures in the types of media was seeded into 5E+5 / 75T flasks, and each culture medium was replaced every two days. The analysis of results was averaged without individual results for the three types of cells, and expressed as a comparison value between media. As a result of comparing the doubling times of the five types of media, the values of C1, C3, and comparison media were shown to be lower than those of the basal medium and C2 medium(FIG. 14). Similarly, the CPDL values were shown to be high in the order of cells cultured in the medium for comparison, C1 and C3 media, basal medium, and C1 medium (FIGs. 15 and 16).

[0073] 10-2: Colony-forming unit (CFU)

[0074] The present inventors compared and analyzed the number of colonies after culturing for 8 days using the cells of Example 4-1 at both conditions of 10 cells / cm2and 20 cells / cm2. As a result, it was found that the cells cultured in C1, C3, and comparison media formed a greater number of colonies compared to the cells cultured in the basal medium and C2 medium, and that the size of the colonies in the comparative media was formed to be relatively larger than that in the C1 and C3 media(FIGs. 17 and 18).

[0075] 10-3: FreSHtracer assay

[0076] The present inventors seeded human adipose-derived stem cells in well plates(6×103cells / well). After culturing for 24 hours, the cells were treated with an antioxidant and cultured for 2 hours, and Mito-FT staining and endpoint measurement were performed.

[0077] As a result of GSH level analysis, the GM value representing the amount of mitochondrial GSH did not show a significant difference. As a result of GSH heterogeneity analysis representing the degree to which the amount of GSH between cells is dispersed, all three types of cells cultured in the above five types of media did not show a significant difference (FIGs. 19 and 20).

[0078] 10-4: Resistance to oxidative stress

[0079] The present inventors seeded human adipose-derived stem cells in well plates(6 × 103cells / well). 1S,3R-RSL3{(1S,3R)-Methyl 2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1-[4-(methoxycarbonyl)phenyl]-1H-pyrido[3,4-b]indole-3-carboxylate, Tocris Bioscience, UK} was treated as an oxidative stress inducer. After culturing for 24 hours, the cells were treated with an antioxidant and cultured for 2 hours, and Mito-FT staining and endpoint measurement were performed.

[0080] As a result of analysis of resistance to oxidative stress, the resistance was shown to be overall high in the order of comparison medium, C3 medium, and C1 medium (FIG. 21).

[0081] 10-5: Anti-inflammatory assay

[0082] The present inventors seeded human peripheral blood mononuclear cells (hPBMCs) labeled with CFSE(i.e., a fluorescence material) which indicates the degree of cell division, into a U-bottom well plate(1 × 105cells / well), and stimulated for 5 days with PHA, which promotes T-cell activation. Then, the activity level was compared and analyzed using a flow cytometer.

[0083] As a result of confirming the inhibitory ability of T-cell proliferation, all of the cells cultured in the five types of media did not show any significant difference. In addition, as a result of analyzing the ability of increasing differentiation of CD4+T-cells into regulatory T-cells, all of the cells cultured in the five types of media did not show any significant difference (FIGs. 22 and 23).

[0084] Summarizing the analysis results of the examples above, as a result of analyzing the 5 types of antioxidation tests including basal medium, C1, C2, C3 media in which an antioxidant was added to the basal medium, and commercial medium for comparison, it was found that in terms of CPDL and CFU, C1 and C3 media showed a doubling level and colony formation ability similar to those of the medium for comparison. While the resistance to oxidative stress was observed to be high in the C3 medium, similar to the medium for comparison, mitochondrial GSH and anti-inflammatory activity did not show any significant difference in all of the 5 types of media above.

[0085] In conclusion, as a result of culturing human adipose-derived stem cells (hAD-MSCs) using a novel composition for culturing stem cells of the present disclosure, which was prepared based on antioxidation enhancing substances selected through a basic screening process, these cells showed resistance to cell proliferation and oxidative stress similar to those in commercial media, confirming that the composition can be used as a culture composition for optimizing stem cell ability.

[0086] The present disclosure has been described with reference to the above-described Examples, but these are merely exemplary and those skilled in the art will understand that various modifications and equivalent other Examples are possible therefrom. Therefore, the true technical protection scope of the present disclosure should be determined by the technical idea of the appended claims.

Claims

1.A medium composition for culturing adipose-derived mesenchymal stem cells, comprising:basal medium;100-150 μg / mL of ascorbic-acid-2-phosphate (AA2P) and 0.5-2 μM vitamin E;5-15 μg / mL of a tomato extract;50-200 μg / mL of an extract ofAilanthus altissimaleaves;200-400 nM baicalein;500-700 nM luteolin;4-6 μM quercetin;10-30 μM ascorbyl-2,6-dipalmitate;5-15 μM vitamin D3;1.5-3.5 μM gamma-glutamyl cystein ester; and5-20 μM / mL of putrescine.2.The medium composition of claim 1, comprising:120-130 μg / mL of AA2P and 0.8-1.5 μM vitamin E;10-12 μg / mL of a tomato extract;70-150 μg / mL of an extract ofAilanthus altissimaleaves;250-350 nM baicalein;550-650 nM luteolin;4.5-5.5 μM quercetin;15-25 μM ascorbyl-2,6-dipalmitate;7-13 μM vitamin D3;1.7-3.2 μM gamma-glutamyl cystein ester; and7-15 μM / mL of putrescine.3.The medium composition of claim 1 or 2, wherein the basal medium is α-MEM and the composition further comprises 5-15% fetal bovine serum (FBS) and 0.5-2% penicillin-streptomycin (PS).4.A method forex vivoculture of adipose-derived stem cells, comprising a step of culturing adipose-derived stem cells isolated outside the body of a subject in the adipose-derived stem cell culture medium of any one of claims 1 to 3.